Companies › Coya Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| COYA 302 Low-dose IL-2 to enhance regulatory T cell function combined with abatacept (CTLA-4 Ig) to | IL2, CD80, CD86 | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07161999 | COYA 302 | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | Neurology | Apr 2027 |
Cash of $36m on 2026-09-30; operating cash outflow about $28m a year; runway about 15 months at that burn, to Jan 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Satellos Bioscience PepGen Cognition Therapeutics DiaMedica Therapeutics IGC Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.